TABLE 3.

Patient- and serum-based Asp-WB kit diagnostic indices according to the various clinical presentations of aspergillosis

Group	n	Asp-WB diagnostic indices			Asp-WB versus IPD*
		Sensitivity (% [95% CI])	Yule Q (95% CI)	DOR (95% CI)	IPDb sensitivity (% [95% CI])	Agreement (% [95% CI])	Cohen's kappa (95% CI)
Patient-based analysis
Aspergillus disease	131	91.6 (0.89–0.94)	0.99 (0.98–0.99)	185.22 (78.79–435.45)	86.3 (0.83–0.89)	84.0 (0.81–0.87)	0.192 (0.027–0.357)
CPA	89	91.0			87.6	87.6
Aspergilloma	10	90.0			100.0	90.0
ABPA	32	93.8			78.1	71.9
Aspergillus colonization	27	74.1 (0.66–0.82)	0.96 (0.94–0.97)	43.74 (15.65–122.20)	59.3 (0.50–0.69)	77.8 (0.70–0.86)	0.512 (0.155–0.869)
Cystic fibrosis positive	15	100.0			73.3	73.3
Cystic fibrosis negative	12	41.7			41.7	83.3
Aspergillosis sensu latoa	158	88.6 (0.86–0.91)	0.98 (0.98–0.99)	119.06 (56.50–250.90)	81.6 (0.79–0.85)	82.9 (0.80–0.86)	0.332 (0.182–0.482)
Serum-based analysis
Aspergillus disease	267	94.0 (0.93–0.95)	0.99 (0.99–1.00)	299.09 (135.62–659.57)	87.6 (0.86–0.90)	86.1 (0.84–0.88)	0.21 (0.10–0.31)
CPA	197	93.4			87.3	82.5
Aspergilloma	13	92.3			100.0	92.3
ABPA	57	96.5			86.0	86.8
Aspergillus colonization	41	73.2 (0.66–0.80)	0.95 (0.94–0.97)	41.75 (17.14–101.66)	53.7 (0.46–0.61)	75.6 (0.69–0.82)	0.50 (0.22–0.78)
Cystic fibrosis positive	18	100.0			72.2	72.2
Cystic fibrosis negative	23	52.2			39.1	78.3
Aspergillosis sensu latoa	308	91.2 (0.90–0.93)	0.99 (0.98–0.99)	159.31 (80.22–316.40)	83.1 (0.81–0.85)	84.7 (0.83–0.87)	0.35 (0.25–0.45)

^aThe Aspergillus disease and Aspergillus colonization groups are included in the aspergillosis sensu lato group.

^bIPD, immunoprecipitin detection assay.